ISMIVS Newsletter 2026 January & February Newsletter ISMIVS

ISMIVS Newsletter 2026 January & February

Newsletter 2026 January & February
2026年1&2月简报

About Us 国际微无创医学会简介

The International Society of Minimally Invasive and Virtual Surgery (ISMIVS, previously known as International Society of Minimally Invasive and Noninvasive Medicine) was founded in July 2013 at the gala of the 1st Yangtze International Summit of Minimally Invasive and Noninvasive Medicine in Chongqing, China. ISMIVS envisions to accelerating the progress in minimally invasive and noninvasive medicine by promoting research, education, communication, and international collaboration.
国际微无创医学会（ISMIVS）是在 2013 年 7 月在中国重庆召开的第一届国际微无创医学长江高峰论坛上宣布成立的，旨在通过学术研究、教育、交流以及国际合作加快微无创医学的发展。

Become a member 注册成为会员 >

Ideas about Young ISMIVS 医路青春专访栏目

Ideas about Young ISMIVS
医路青春专访栏目

In July 2023, the Young ISMIVS Committee was formally established in order to respond to the development trend of minimally invasive and noninvasive medicine, and further consolidate the core group of young physicians.
为顺应微无创医学发展的趋势，进一步凝聚中青年微无创医学骨干的力量，推动微无创医学的发展。2023年7月，国际微无创医学会“青年委员会”（以下简称“青委会”）正式成立。
As the youth force of the new era in the field of minimally invasive and noninvasive medicine, the Young ISMIVS Committee carries the important mission of enlightening medical innovation and leading the development of this field. It will become a solid pillar to promote the breakthroughs in minimally invasive and noninvasive medicine to new heights through its unique vitality and profound deposits.
青委会作为微无创领域新时代的青春力量，承载着启迪医学创新、引领微无创技术发展的重要使命，将凭借其独特的创新活力和深厚的专业积淀，成为推动微无创领域不断突破、迈向新高峰的坚实砥柱。
In medicine, a group of passionate young physicians, who harbor the love and persistence for minimal invasiveness and non-invasiveness, keep exploring and moving forward. They are the members of the Young ISMIVS Committee, who contribute to the development of this field with their enthusiasm and wisdom.
在医学的广阔天地里，这样一群热血的青年医者，他们怀揣着对微无创医学的热爱与执着，不断探索、不断前行。他们，正是青委会的成员，他们以青春的热情与智慧，为微无创医学的发展贡献着自己的力量。
In conjunction with Da Yi Wei Ke, we are now introducing the first interview show – Ideas about Young ISMIVS. Let's get closer to this group of young doctors, listen to their stories on the path of minimally invasive and non-invasive medicine, feel their passion and persistence, and witness the bright future together.
国际微无创医学会青年委员会联合大医微课策划出品，首档人物专访节目《医路青春》正在播出。让我们走近这群青年医者，聆听他们在微无创路上的成长故事，感受他们的热情与执着，共同见证微无创医学的辉煌未来。

Ideas about Young ISMIVS with:
本期嘉宾：

Liu Xiaofang
Chief Physician
Suining Central Hospital
刘晓芳
主任医师
遂宁市中心医院

-Vice Chair (Clinical Training) of the Young ISMIVS Committee
-Member of the Third Committee of the Minimally Invasive Medicine Specialty of the Chinese Medical Doctor Association
-Member of the Reproductive Medicine Branch of the Chinese Association of Traditional Chinese Medicine
-国际微无创医学会青年委员会副主任委员（临床培训方向）
-中国医师协会微创医学专业第三届委员会委员
-中华中医药学会生殖医学分会委员

Watch the interview:

https://youtu.be/fVWJRq7etzU?si=TPg5zyv0amMPqYKl

观看本期采访：

https://mp.weixin.qq.com/s/P_Jh9goSvpB1A1TjC2hotA

News 新闻

Parallel Session of ISMINIM 2025:
Treatment Strategies for Liver and Pancreatic Cancer
2025 微无创医学长江论坛分会场精彩速递：肝癌及胰腺癌的治疗策略

On June 22, 2025, the parallel session of“Treatment Strategies for Liver and Pancreatic Cancer” of the 2025 Yangtze Summit of Minimally Invasive and Noninvasive Medicine & Annual Academic Conference of the Focused Ultrasound Therapy Branch of Chongqing Medical Association was rounded off.
6 月 22 日，2025 微无创医学长江论坛暨重庆市医学会聚焦超声治疗分会学术年会分论坛“肝癌及胰腺癌的治疗策略”圆满举行。

The session was chaired by Gong Xuejun, Director of the Department of Pancreatic Surgery at Xiangya Hospital of Central South University; Li Yun from the Department of Oncology at Changji Prefecture People’s Hospital; Yu Jun, Director of the Center for Pancreatic Cancer Prevention and Treatment at Tianjin Cancer Hospital; and Gabriel Massaferro from Uruguay.
中南大学湘雅医院胰腺外科主任龚学军、昌吉州人民医院肿瘤科李赟、天津肿瘤医院胰腺肿瘤防治中心主任余俊、Gabriel Massaferro 等人担任主持。
Prof. Simon Tsung of the University of Hong Kong shared minimally invasive surgical strategies for treating liver tumors in difficult-to-reach locations, highlighting how precise localization and minimally invasive techniques can enhance surgical safety, and discussing the value of multidisciplinary collaboration in complex cases.
香港大学曾庆衍教授分享了治疗困难位置肝脏肿瘤的微无创手术策略，重点介绍了如何通过精准定位和微创技术提高手术安全性，并探讨了多学科协作在复杂病例中的应用价值。
Xu Qing, the academic leader of the Department of Oncology at Shanghai Tenth People’s Hospital Affiliated to Tongji University, conducted an in-depth discussion on the regulatory role and impact of high-intensity focused ultrasound (HIFU) on tumor immunotherapy. He pointed out that HIFU not only directly ablates tumors but also activates local immune responses, thereby opening up new avenues for research into combination immunotherapy.
同济大学附属上海市第十人民医院肿瘤科学科带头人许青深入探讨了高强度聚焦超声对肿瘤免疫治疗的调控和影响，指出高强度聚焦超声不仅能直接消融肿瘤，还能激活局部免疫反应，为联合免疫治疗提供了新的研究方向。
Prof. Mohamed Hamed, the Vice President of ISMIVS, elaborated on the application of high intensity focused ultrasound in colorectal metastases in the liver, emphasizing its advantages of precise ablation and low trauma, and shared his experience in improving efficacy and reducing complications.
国际微无创医学会副主席 Mohamed Hamed 结合临床实践，详细阐述了高强度聚焦超声在肝脏结直肠转移病灶中的应用，强调其精准消融和低创伤优势，并分享了提高疗效和减少并发症的经验。
Wu Yakun, a member of the Party Committee and Vice President of Suining Central Hospital, analyzed the therapeutic value of high-intensity focused ultrasound (HIFU) in the treatment of liver cancer from the perspective of a surgeon. He noted that HIFU can serve as a complementary or alternative option to surgery, particularly for elderly patients or those with multiple comorbidities; however, further long-term follow-up data is still needed to support its use.
遂宁市中心医院党委委员、副院长吴涯昆从外科医生的视角分析了高强度聚焦超声在肝癌治疗中的应用价值，认为高强度聚焦超声可作为手术的补充或替代方案，尤其适用于高龄或合并症较多的患者，但仍需更多长期随访数据支持。
Aleksandr Pavlovskiy, a senior researcher at the Russian Scientific Center for Radiation and Surgical Technologies, reported a case study on the treatment of locally advanced pancreatic cancer using high-intensity focused ultrasound in combination with intra-arterial oil-based chemotherapeutic embolization and radiation therapy. The study demonstrated the synergistic effects of this multimodal approach, offering a new treatment option for patients with advanced pancreatic cancer.
俄罗斯放射与外科技术科学中心首席研究员 Pavlovskiy Aleksandr 报告了高强度聚焦超声联合动脉内油性化疗栓塞和放疗治疗局部晚期胰体癌的病例，展示了多模式治疗的协同效应，为晚期胰腺癌患者提供了新的治疗选择。
Prof. Zhou Kun, Deputy Director of the HIFU Oncology Center at the Second Affiliated Hospital of Chongqing Medical University, drew on his clinical experience to discuss the indications and technical considerations for high-intensity focused ultrasound (HIFU) therapy in the treatment of pancreatic cancer. He noted that the therapy can effectively relieve pain and prolong survival, but emphasized the need for strict patient selection to ensure treatment efficacy.
重庆医科大学附属第二医院海扶肿瘤中心副主任周崑结合临床经验，探讨了高强度聚焦超声治疗胰腺癌的适应症和技术要点，指出其可有效缓解疼痛并延长生存期，但需严格筛选患者以确保疗效。
Prof. Yang Wuwei of the General Hospital of the Chinese People’s Liberation Army systematically summarized the clinical value of focused ultrasound ablation in advanced pancreatic cancer, highlighting its advantages in local control and symptom relief, and outlined future directions for technological optimization.
中国人民解放军总医院杨武威系统总结了聚焦超声消融在进展期胰腺癌中的临床价值，强调其在局部控制和症状改善方面的优势，并展望了未来技术优化的方向。
Prof. Feng Gang from the Department of Oncology at Mianyang Central Hospital provided a detailed overview of the current applications of high-intensity focused ultrasound (HIFU) in the treatment of pancreatic tumors, including key technical procedures and efficacy assessment. He concluded that the technique is safe and feasible, but that treatment protocols need to be further standardized to improve therapeutic outcomes.
绵阳市中心医院肿瘤科冯岗详细介绍了高强度聚焦超声在胰腺肿瘤中的应用现状，包括技术操作要点和疗效评估，认为其安全可行，但需进一步规范治疗流程以提高疗效。

Watch the playback of the Summit:

https://www.youtube.com/playlist?list=PLWbjlVbxcLm3p9sE4xg3Z8YdcvZ4xOuYj

观看会议回放：

https://live.dayiweike.com/video/huikan/1980?m=jin

New Perspective in Focused Ultrasound 聚焦超声新视角

Factors influencing the volume reduction rate of ultrasound-guided high-intensity focused ultrasound for breast fibroadenoma
影响超声引导下高强度聚焦超声治疗乳腺纤维腺瘤体积缩减率的因素

Volume reduction rate and its influencing factors in solitary uterine fibroids classified as Funaki types I and II after ultrasonography-guided high intensity focused ultrasound ablation: a prospective cohort study

超声引导下高强度聚焦超声消融术后，Funaki I 型和 II 型单发子宫肌瘤的体积缩小率及其影响因素：一项前瞻性队列研究

This study aimed to explore the volume reduction rate (VRR) and its influencing factors in solitary uterine fibroids classified as Funaki type I and II after ultrasonography-guided high-intensity focused ultrasound (USgHIFU) ablation.

本研究旨在探讨经超声引导的高强度聚焦超声（USgHIFU）消融术后，Funaki I 型和 II 型单发子宫肌瘤的体积缩减率（VRR）及其影响因素。

It enrolled 191 patients with uterine fibroids who underwent USgHIFU ablation. To calculate the VRR, fibroid dimensions were measured using ultrasonography at 3, 6 and 12 post-treatment months. The primary endpoint was the VRR at 12 post-treatment months. The secondary endpoints included the non-perfused volume ratio (NPVR) and VRR at three and six months.

本研究纳入 191 例接受 USgHIFU 消融治疗的子宫肌瘤患者。为计算 VRR，于术后第 3、6及12 个月通过超声检查测量肌瘤尺寸。主要终点为术后 12 个月时的VRR。次要终点包括术后 3 个月和 6 个月时的无灌注体积比（NPVR）及VRR。

The mean VRR for all 191 patients was 29.9%, 39.6% and 44.0% at 3, 6 and 12 post-treatment months, respectively. Subgroup analysis demonstrated a significant volume reduction across groups stratified by maximum fibroid diameter, Funaki type and NPVR. Univariable logistic analysis identified the following factors significantly associated with a higher VRR at 12 months: age ≥35 years (odds ratio [OR] 3.960, 95% confidence interval [CI] 1.405-11.159), presence of menstrual abnormalities (OR 1.936, 95% CI 1.075-3.485), moderate enhancement (OR 2.340, 95% CI 1.193-4.591), anteverted uterus (OR 2.020, 95% CI 1.034-4.025) and lymphocyte count <1.8 × 109/L (OR 2.963, 95% CI 1.265-5.993). Multivariable logistic analysis revealed that age ≥35 years (OR 3.436, 95% CI 1.188-9.947) and lymphocyte count <1.8 × 109/L (OR 2.113, 95% CI 1.142-3.908) were significantly associated with high VRR.

在所有 191 名患者中，治疗后 3 个月、6 个月和 12 个月的平均VRR分别为 29.9%、39.6%和44.0%。亚组分析显示，按肌瘤最大直径、Funaki 分型和非病灶性缩小（NPVR）分层后，各组均呈现显著的体积缩小。单变量逻辑回归分析确定了以下与 12 个月时更高 VRR 显著相关的因素：年龄≥35岁（比值比 [OR] 3.960，95% 置信区间 [CI] 1.405-11.159）、存在月经异常（OR 1.936，95% CI 1.075-3.485）、中度强化（OR 2.340，95% CI 1. 193-4.591)、子宫前倾（OR 2.020，95% CI 1.034-4.025）以及淋巴细胞计数<1.8 × 109/L（OR 2.963，95% CI 1.265-5.993）。多变量逻辑回归分析显示，年龄 ≥35岁（OR 3.436，95% CI 1.188-9.947）和淋巴细胞计数<1.8 × 109/L（OR 2.113，95% CI 1.142-3.908）与高 VRR 显著相关。

The uterine fibroid volume progressively decreased after USgHIFU ablation. Age ≥35 years and lymphocyte count <1.8 × 109/L were significantly associated with high VRR.

经超声引导的高强度聚焦超声（USgHIFU）消融术后，子宫肌瘤体积逐渐减小。年龄 ≥35 岁和淋巴细胞计数 <1.8×10⁹/L 与高体积缩小率（VRR）显著相关。